V114

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

InfluenzaImmunodeficiencySickle Cell DiseaseAcute Otitis Media

1053 competitors in Influenza

#DrugCompanyPhaseTrials

1

V114

Merck & Co.

Phase 3

12

Fluzone

Sanofi

Preclinical

163

Fluzone

GSK

Preclinical

374

Crestor

AstraZeneca

Preclinical

15

Trexall

Alnylam Pharmaceuticals

Preclinical

16

Avigan

AAppili Therapeutics Inc.

Preclinical

67

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

308

COMIRNATY

Pfizer

Preclinical

19

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

110

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

1Show 12 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immunogenicity14 trials

Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)

Completed·Merck & Co.·Phase 3·NCT05158140·850 enrolled

Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033)

Completed·Merck & Co.·Phase 3·NCT04384107·694 enrolled

Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)

Completed·Merck & Co.·Phase 3·NCT04016714·1,191 enrolled

Show 11 more trials

Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)

Completed·Merck & Co.·Phase 1/2·NCT02037984·341 enrolled

A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)

Completed·Merck & Co.·Phase 1/2·NCT02531373·338 enrolled

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)

Completed·Merck & Co.·Phase 2·NCT02987972·1,051 enrolled

Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)

Completed·Merck & Co.·Phase 1·NCT03848065·133 enrolled

Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024)

Completed·Merck & Co.·Phase 3·NCT03885934·606 enrolled

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)

Completed·Merck & Co.·Phase 3·NCT03480763·652 enrolled

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

Completed·Merck & Co.·Phase 3·NCT03893448·1,720 enrolled

Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036)

Completed·Merck & Co.·Phase 3·NCT04633226·58 enrolled

Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)

Completed·Merck & Co.·Phase 2·NCT02573181·253 enrolled

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)

Completed·Merck & Co.·Phase 3·NCT04031846·1,184 enrolled

Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE)

Completed·Merck & Co.·Phase 3·NCT03950622·1,205 enrolled

Infants2 trials

A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)

Completed·Merck & Co.·Phase 3·NCT03620162·900 enrolled

A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)

Completed·Merck & Co.·Phase 3·NCT03692871·2,409 enrolled

Immunodeficiency2 trials

Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)

Completed·Merck & Co.·Phase 3·NCT03921424·407 enrolled

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)

Completed·Merck & Co.·Phase 3·NCT03480802·302 enrolled

Vaccine1 trial

A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003)

Completed·Merck & Co.·Phase 2·NCT01215188·1,152 enrolled

Allogeneic Hematopoietic Stem Cell Transplant Recipient1 trial

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)

Completed·Merck & Co.·Phase 3·NCT03565900·277 enrolled

5 more indications

Acute otitis media1 trial

V114 and Acute Otitis Media (V114-032/PNEU-ERA)

Completed·Merck & Co.·Phase 3·NCT04193215·7,119 enrolled

Adult1 trial

Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)

Completed·Merck & Co.·Phase 3·NCT03950856·2,340 enrolled

Sickle Cell Disease1 trial

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)

Completed·Merck & Co.·Phase 3·NCT03731182·104 enrolled

Pneumococcal Disease1 trial

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)

Completed·Merck & Co.·Phase 3·NCT03547167·1,515 enrolled

Influenza1 trial

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)

Completed·Merck & Co.·Phase 3·NCT03615482·1,200 enrolled

Details

Drug Info

Related News